Guardant Health Inc. (GH)
45.64
1.93 (4.42%)
At close: Apr 14, 2025, 3:06 PM
4.42% (1D)
| Bid | 45.32 |
| Market Cap | 5.63B |
| Revenue (ttm) | 739.02M |
| Net Income (ttm) | -436.37M |
| EPS (ttm) | -3.56 |
| PE Ratio (ttm) | -12.82 |
| Forward PE | -24.05 |
| Analyst | Buy |
| Ask | 45.87 |
| Volume | 1,058,946 |
| Avg. Volume (20D) | 2,327,319 |
| Open | 44.72 |
| Previous Close | 43.71 |
| Day's Range | 44.33 - 45.77 |
| 52-Week Range | 15.81 - 50.89 |
| Beta | 1.45 |
About GH
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test fo...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Oct 4, 2018
Employees 1,999
Stock Exchange NASDAQ
Ticker Symbol GH
Website https://guardanthealth.com
Analyst Forecast
According to 20 analyst ratings, the average rating for GH stock is "Buy." The 12-month stock price forecast is $52, which is an increase of 13.94% from the latest price.
Stock ForecastsNext Earnings Release
Guardant Health Inc. is scheduled to release its earnings on Apr 30, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+18.95%
Guardant Health shares are trading higher after th...
Unlock content with
Pro Subscription
1 month ago
+7.04%
Guardant Health shares are trading higher after Piper Sandler maintained an Overweight rating and raised the price target from $34 to $50.
